Brezosiran
RNA / oligonucleotide
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other Huntingtin (HTT) drugs
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Huntington's Disease: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Brezosiran: this drug | Phase 1 | RNA / oligonucleotide | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| Valbenazine (Ingrezza) | Approved | Small molecule | vesicular monoamine transporter 2 (VMAT2) | Partial signal | NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD). | |
| Votoplam | Phase 3 | Small molecule | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tanruprubart | Phase 2 | Monoclonal antibody | Complement C1q | not yet graded | No reviewed efficacy summary in this indication | |
| Ifezuntirgene Inilparvovec | Phase 1/2 | Gene therapy / editing | Huntingtin (HTT) gene | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-003 | Phase 1/2 | RNA / oligonucleotide | Huntingtin (HTT) | Weak signal | NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). | |
| RG6662 | —(overall) | Gene therapy / editing | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Brezosiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.